Dexcom Announces Upcoming Virtual Conference Presentations

Dexcom Announces Upcoming Virtual Conference Presentations

SAN DIEGO–(BUSINESS WIRE)–DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming virtual investor conferences:

  • Steve Pacelli, Executive Vice President Strategy and Corporate Development will present on behalf of the company at the Stifel Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20am (EST).
  • Steve Pacelli, Executive Vice President Strategy and Corporate Development will present on behalf of the company at the Piper Sandler Healthcare Conference on Tuesday, December 1, 2020 at 3:00pm (EST).

Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com/ and will be archived there for future reference.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

DexCom, Inc.

Steven R. Pacelli

Executive Vice President, Strategy and Corporate Development

(858) 200-0200

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Diabetes Health Medical Devices

MEDIA:

Logo
Logo

Primerica Board Members Cynthia N. Day and Beatriz “Bea” Perez Recognized for Board Leadership Excellence

Primerica Board Members Cynthia N. Day and Beatriz “Bea” Perez Recognized for Board Leadership Excellence

DULUTH, Ga.–(BUSINESS WIRE)–
Primerica, Inc. (NYSE:PRI), a leading provider of financial services to middle-income families throughout North America, is proud to announce that two members of its Board of Directors have been recognized for excellence in Board leadership.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201112005105/en/

Cynthia N. Day, President and CEO, Citizens Trust Bank (Photo: Business Wire)

Cynthia N. Day, President and CEO, Citizens Trust Bank (Photo: Business Wire)

Cynthia N. Day, President and CEO of Citizens Trust Bank, has received the Lettie Pate Whitehead Evans Award for an outstanding female board member from OnBoard, a leading authority on women in the boardroom and executive suites of Georgia public companies. The award is presented annually to a female board member who has served as an outstanding role model for advancing OnBoard’s mission of increasing the number of women in executive leadership and on corporate boards.

Beatriz “Bea” Perez, Senior Vice President and Chief Communications, Public Affairs, Sustainability and Marketing Assets Officer for The Coca-Cola Company, was recently named to Latino Leaders Magazine’s 2020 list of Latinos on Boards. Latino Leaders Magazine strives to advance the Latino Community by promoting the stories of success and leadership, bringing leaders together through its magazine, gatherings, and social media platforms, as well as inspiring them to connect work together for a better future.

Glenn Williams, Primerica Chief Executive Officer, said, “We are fortunate to have both Cynthia and Bea serve on our Board of Directors. Their leadership helps ensure that diversity, unity, and equality for all people are more than just words at Primerica. We congratulate them for receiving these honors, and we are proud of their commitment to creating opportunities for the diverse families that we serve.”

Ms. Day was elected to Primerica’s Board in January 2014 and Ms. Perez was elected to Primerica’s Board in May 2014.

About Primerica, Inc.

Primerica, Inc., headquartered in Duluth, GA, is a leading provider of financial services to middle-income households in the United States and Canada. Independent licensed representatives educate Primerica clients about how to better prepare for a more secure financial future by assessing their needs and providing appropriate solutions through term life insurance, which we underwrite, and mutual funds, annuities and other financial products, which we distribute primarily on behalf of third parties. We insured over 5 million lives and had approximately 2.5 million client investment accounts at December 31, 2019. Primerica, through its insurance company subsidiaries, was the #2 issuer of Term Life insurance coverage in North America in 2019. Primerica stock is included in the S&P MidCap 400 and the Russell 1000 stock indices and is traded on The New York Stock Exchange under the symbol “PRI.”

Primerica, Inc.

Media:

Keith Hancock

866-694-0420

[email protected]

Investors:

Nicole Russell

866-694-0420

Email: [email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo
Logo
Photo
Photo
Beatriz “Bea” Perez, Senior Vice President and Chief Communications, Public Affairs, Sustainability and Marketing Assets Officer for The Coca-Cola Company (Photo: Business Wire)
Photo
Photo
Cynthia N. Day, President and CEO, Citizens Trust Bank (Photo: Business Wire)

Reprise Emerges from Stealth; Announces Demo Creation Platform and $3.2 Million in Seed Funding

No-code Platform Allows Sales and Marketing Teams to Build Demos Using Any Existing Web Application

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) — Reprise, the demo creation platform company, today emerged from stealth and announced its $3.2 million seed round, co-led by Glasswing Ventures and Accomplice Ventures. The company unveiled its category creator Reprise Demo Creation Platform, enabling sales and marketing teams to capture, edit, and deploy software product demos based on their existing production application. Funding, which was secured in May 2020, has allowed Reprise to deepen the technology of the platform and secure early customer traction.

Enterprise sales and marketing teams struggle to create a demo version of their software which they can show to prospects. Revenue teams want “product-led growth” but do not have a suitable product.

Reprise’s platform enables business users on revenue teams to capture, edit, and deploy an application that feels identical to their production environment. Revenue teams can then use this for sales calls, or for creating a self-service demo on their website.

“Building and maintaining a demo environment was a massive engineering cost at multiple previous companies for our founding team. We knew this was a problem worth solving for any B2B software company,” said Bryan Stevenson, Co-Founder and CEO of Reprise.

“We are excited to be a foundational investor in Reprise and to work with Sam Clemens, Bryan Stevenson, Joe Caprio and Evan Powell, a team of repeat entrepreneurs who have extensive experience in building enterprise software startups in the sales and marketing space,” said Rudina Seseri, Founder and Managing Partner, Glasswing Ventures.

“We back founders. We backed this team at InsightSquared to do revenue analytics, and we’re excited to back them again to do a revenue product platform,” said Jeff Fagnan, Founding Partner at Accomplice.

The Reprise Demo Creation Platform is available immediately and more information can be found at www.getreprise.com.

About Reprise


Reprise
is the Demo Creation Platform Company that enables software companies’ revenue teams to bring their product to life with customized demos, website based product tours, and emailable product experiences. Founded in 2020, Reprise is a private company headquartered in Boston, MA.

About Glasswing Ventures

Glasswing Ventures is an early-stage venture capital firm dedicated to investing in the next generation of AI and frontier technology startups that enable the rise of the intelligent enterprise. For more information about the firm please visit: www.glasswing.vc

About Accomplice

Accomplice is a seed-led venture capital firm that embraces risk, and is the most determined, patient capital partner for entrepreneurs building things that matter. We have been part of the origin story of AngelList, Carbon Black, DraftKings, Integral Ad Science, Hopper, PillPack, Plastiq, Recorded Future, Veracode, and Zoopla. Accomplice has pioneered a community approach through platforms like Spearhead, BOSS, Rev, and TUGG. Based in Boston and San Francisco.

Media Contact Info:
Evan Powell
[email protected]
+1 (215) 801-1637

REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 2020

REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 2020

All economic indicators have substantially improved:

  • Consolidated turnover of €908.3 million (+4.9%)
  • EBITDA of €141.1 million (+3.6%)
  • EBIT of €114.4 million (+5.3%)
  • Pre-tax profit of €113.8 million (+5.6%)
  • Positive Net Financial Position of €135.6 million.

TURIN, Italy–(BUSINESS WIRE)–
Today, the Board of Directors of Reply [MTA, STAR: REY] approved the results as at 30 September 2020.

The Group’s consolidated turnover in the first nine months of the year reached €908.3 million, an increase of 4.9% compared to €866.2 million recorded on 30 September 2019.

All indicators are positive for the period. Consolidated EBITDA was €141.1 million, an increase of 3.6% compared to the €136.2 million recorded in September 2019.

EBIT, from January to September, was €114.4 million, which is an increase of 5.3% compared to €108.6 million at September 2019.

Pre-tax profit, from January to September 2020, was €113.8 million (+5.6% compared to €107.7 million in 2019).

For the third quarter of the year, the Group’s performance is equally positive, with consolidated turnover for the period of €293.1 million, an increase of 0.2% compared to 2019.

EBITDA, from July to September 2020, was equal to €50.9 million, with an EBIT of €40.2 million and pre-tax profit of €38.6 million.

As at 30 September 2020, the Group’s net financial position was positive at €135.6 million. The net financial position as at 30 June 2020 was positive for €122.6 million.

“Despite the difficulties related with the effects of the various lockdowns, Reply was able to achieve positive results in the first nine months of 2020, both in terms of turnover and margins; the third quarter was also characterised by an upward trend”, said Reply Chairman Mario Rizzante after the Board of Directors meeting.

“This has allowed us to continue on our development path, both by expanding Reply’s offering in North America and in Europe, and by investing in new skills, especially in areas such as the cloud, artificial intelligence applications, connected vehicles and solutions that support digitisation and automation of main business processes”, continued Mario Rizzante.

The manager responsible for preparing the company’s financial reports, Dr Giuseppe Veneziano, states in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company’s records, ledgers and accounting entries.

Reply

Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com

This press release is a translation, the Italian version will prevail.

Media Contacts

Reply

Fabio Zappelli

[email protected]

Tel. +390117711594

Investor Relation Contacts

Reply

Riccardo Lodigiani

[email protected]

Tel. +390117711594

Michael Lueckenkoetter

[email protected]

Tel. +49524150091017

KEYWORDS: Germany Europe United Kingdom Italy

INDUSTRY KEYWORDS: Software Social Media Internet Consulting Data Management Communications Professional Services Technology

MEDIA:

Logo
Logo

Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar “Oral Delivery of Therapeutic Proteins – Oramed Story” on November 18, 2020

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific Officer Dr. Miriam  Kidron will join Premas Biotech’s Co-Founder and Managing Director Dr. Prabuddha Kundu and Co-Founder and Chief Operating Officer Dr. Nupur Mehrotra in Part 2 of a webinar titled “Oral Delivery of Therapeutic Proteins – Oramed Story” on Wednesday, November 18, 2020 at 10:00 a.m. ET.  Prof. Hershko is a member of the Oramed Scientific Advisory Board.

Investors are invited to register for the webinar at:   https://lnkd.in/djXe94H

Throughout history, oral administration has been regarded as the most convenient mode of drug delivery, as it requires minimal expertise and invasiveness. Although oral delivery works well for small-molecule drugs, oral delivery of proteins and peptides has been limited by acidic conditions in the stomach and low permeability across the intestinal epithelium.

Oramed has made tremendous strides in the oral delivery of proteins and peptides, beginning with its oral insulin ORMD-0801 which is entering Phase 3 trials in the U.S.

On Wednesday at 10:00 a.m. ET, in the conclusion of a two-part webinar series, the session will focus on the “Oral Delivery of Therapeutic Proteins – Oramed Story”.

About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

For more information, please visit www.oramed.com.

Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes or revolutionizing the treatment of diabetes with our products. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Company Contact

Estee Yaari

+1-844-9-ORAMED
[email protected]

Logo – https://mma.prnewswire.com/media/647544/Oramed_Pharmaceuticals_Logo.jpg

Cision View original content:http://www.prnewswire.com/news-releases/nobel-laureate-oramed-sab-member-prof-avram-hershko-and-oramed-cso-dr-miriam-kidron-to-be-featured-on-biotalknology-webinar-oral-delivery-of-therapeutic-proteins—oramed-story-on-november-18-2020-301171749.html

SOURCE Oramed Pharmaceuticals Inc.

The Princess Margaret Cancer Foundation presses start with Quest to Conquer Cancer

The new fundraising initiative encourages gamers, spectators and supporters of all abilities to raise funds through gaming for cancer research

Toronto, Nov. 12, 2020 (GLOBE NEWSWIRE) — The Princess Margaret Cancer Foundation has kicked-off its new fundraising initiative, Quest to Conquer Cancer, to unite video game streamers, spectators and supporters all over the world to fundraise for cancer research through live gaming broadcasts. Quest will culminate in a week-long fundraising finale — Quest Together, Conquer Together — which will start on December 5 and run through to December 12.

All money raised through Quest to Conquer Cancer directly supports more than 1,300 researchers and scientists as they continue to push boundaries and set global standards in cancer care. This means earlier detection, advanced research, improved diagnostics to better understand the individual nature of each cancer and targeted treatments, ultimately leading to improved outcomes for cancer patients worldwide.

“Time and time again, we have seen the gaming community show passion and ingenuity to support charitable causes while doing what they love,” said Michael Burns, President and CEO at The Princess Margaret Cancer Foundation. “With Quest to Conquer Cancer, we want to inspire this community to play a key role in support of cancer research.”

Quest has no fundraising minimum and features game challenges, prize drops and a unique reward system for reaching fundraising milestones. All donations to streamers or through the Quest to Conquer Cancer website go directly to fund cancer research at The Princess Margaret Cancer Centre. This inaugural year’s goal is to raise $1 million.

The Princess Margaret Cancer Foundation is partnering with gaming leaders and brands, including Stonemountain64, Nick Eh 30 and Digital Extremes, to create unique gaming experiences throughout the Quest campaign. These events will act as touch points to bring the community together and celebrate supporters. Quest has already attracted the attention of esports organizations around the world, such as Chaos EC, Electrify Esports and BOOM Esports.

“Cancer is a disease that impacts everyone – whether it’s your mother, father, sibling or friend,” said David Steinberg, also known as StoneMountain64. “As a Quest partner, it’s been incredible to see gamers from all over the world come together, share their personal stories and raise funds in support of ground-breaking cancer research.”

In December, Quest Together, Conquer Together will bring content creators, esports organizations and game publishers together for a weeklong charity marathon stream and celebration. To unite participants from across the globe, Quest fundraisers will be encouraged to host their fundraising finale using the hashtag #QuestTogether.

“We did not become one of the top five cancer research centres in the world alone. We got here with the help of our community, which we’re thrilled to be expanding with Quest,” said Burns.

To learn more about this initiative or join as a Quest fundraiser, visit QuestToConquerCancer.com.

-30-

About Princess Margaret Cancer Foundation

Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education at UHN. All are research hospitals affiliated with the University of Toronto. For more information: www.theprincessmargaret.ca

Ceilidh McMeekin
Princess Margaret Cancer Foundation
587-227-5459
[email protected]

Envestnet and RiskPro® Announce Enablement of Enterprises to Mitigate Regulatory Risk from Advisor-Directed Portfolios

Scheduled to Go Live in Early 2021, the Integration Will Strengthen Transparency & Documentation Capabilities for Enterprises and Advisors

PR Newswire

NEWPORT BEACH, Calif. and CHICAGO, Nov. 12, 2020 /PRNewswire/ — RiskPro and Envestnet, Inc. (NYSE: ENV) announce an integration which will enable investment advisors to build and manage client portfolios with less regulatory risk. The strategic relationship between the two companies will allow RiskPro’s proposal generation, portfolio construction, and automated risk surveillance software to function within existing enterprise workflows on the Envestnet unified advice platform.

“This is not just an important strategic relationship—this is something much bigger that will set a new, higher standard for investment account suitability and regulatory transparency,” said Nick Scalzo, Co-Founder and Co-CEO of RiskPro. “Working together, RiskPro and Envestnet have the opportunity to provide more advisors across the country with tools that help align client portfolios with each client’s individual risk tolerance—increasing the likelihood of meeting client expectations, while reducing the enterprise’s regulatory risk and liability.”  

RiskPro’s Perpetual Suitability software (https://www.riskproadvisor.com/perpetual-suitability), which will be offered to Envestnet’s enterprise customers when the integration goes live in early 2021, helps advisors’ clients determine their own Personal Risk Budget (PRB) using a fully documented process that clearly defines risk in terms that clients can understand—maximum annual dollar gain or loss potential. Once a client’s PRB has been calculated, advisors affiliated with Envestnet enterprise customers can make investment recommendations with a 98% statistical probability that maximum risk tolerances will not be exceeded over any given 12-month period. This statistical probability applies to institutional model portfolios as well as to portfolios that investment advisors construct on their own.

RiskPro’s technology allows each enterprise to set its own surveillance rules for monitoring the risk of a client’s portfolio, as compared to the client’s PRB, on a daily basis. Enterprise home offices and the advisors are alerted if the risk of a client’s portfolio falls outside of the surveillance rules set by the enterprise, and all steps required by the home office for realignment are well-documented.

“Our strategic relationship with RiskPro will strengthen the essential advice that enterprises deliver to clients, while empowering their advisors to help clients achieve financial wellness,” said Blake Wood, Senior Vice President and Director of Product Strategy at Envestnet. “We consistently seek ways to broaden the data-driven intelligence we can offer advisors, and RiskPro’s technology solutions help advisors at enterprises make better, risk-managed investment recommendations for investors. This is what makes RiskPro an ideal strategic partner for Envestnet, and we look forward to the launch of our integration.”  

To learn more about Envestnet and RiskPro’s integration visit the Envestnet Advisor Summit site for a new technology session in the coming weeks: https://www.envestnet.com/advisorsummit.

About RiskPro

RiskPro® is a revolutionary technology platform that provides risk profiling, portfolio construction, and automated account surveillance. Serving as the World’s First Virtual Portfolio Strategist, RiskPro evaluates and communicates risk for investors, advisors, and home offices, utilizing a common language that is simple to understand. RiskPro was developed by ProTools, LLC., a RegTech innovator headquartered in Newport Beach, CA. To learn more about how RiskPro enables financial institutions to achieve Perpetual Suitability, visit www.riskproadvisor.com or contact Jeff Olsen, President, at (949) 922-3764 or via email at [email protected]. Follow us on LinkedIn.

About Envestnet

Envestnet, Inc. (NYSE: ENV) is transforming the way financial advice and wellness are delivered. Our mission is to empower advisors and financial service providers with innovative technology, solutions, and intelligence to make financial wellness a reality for everyone. Over 105,000 advisors and more than 5,100 companies including: 17 of the 20 largest U.S. banks, 47 of the 50 largest wealth management and brokerage firms, over 500 of the largest RIAs, and hundreds of FinTech companies—leverage the Envestnet platform to grow their businesses and client relationships.

For more information on Envestnet, please visit www.envestnet.com, subscribe to our blog, and follow us on Twitter (@ENVintel) and LinkedIn.

RiskPro and Envestnet are separate and unaffiliated firms, and are not responsible for each other’s services or policies.  This release should not be construed as a recommendation or endorsement of any particular product, service, or firm.

Media Contacts

Julie Mochan, AIF®
RiskPro®
949.259.6928
[email protected]

Dana Taormina

JConnelly for Envestnet
973.647.4626
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/envestnet-and-riskpro-announce-enablement-of-enterprises-to-mitigate-regulatory-risk-from-advisor-directed-portfolios-301171810.html

SOURCE Envestnet, Inc.; RiskPro

Playboy Invests in Digital Commerce Expansion With Senior Hires

Playboy Invests in Digital Commerce Expansion With Senior Hires

Two Strategic Leaders Tapped to Enhance Company’s Data and Digital Presence

LOS ANGELES–(BUSINESS WIRE)–
Playboy Enterprises, Inc. (the “Company” or “Playboy”), which recently announced it would return to the public markets via a merger with Mountain Crest Acquisition Corp (Nasdaq: MCAC) (“Mountain Crest”), a special purpose acquisition company, has recently made two strategic hires – AJ Saltzman, Vice President, Digital Product, and Tittu Nellimoottil, Senior Vice President, Data, to enhance and expand the Company’s growing digital commerce platform.

“On behalf of the entire Playboy organization, I am delighted to welcome AJ and Tittu to the team,” said Ben Kohn, CEO of Playboy. “AJ and Tittu will be pivotal in the development of our digital commerce experience as we build towards our goal of creating the leading pleasure and leisure lifestyle platform for men and women around the world.”

AJ Saltzman, VP Digital Product

Saltzman’s strategy to build out the Company’s e-commerce destinations is not to approach them solely as places where commercial transactions are made, but as experiences that envelop a consumer in the Playboy lifestyle of sophisticated fun and pleasure. Her belief is that everything should be done through the lens of the consumer and works to ensure users feel they have an unparalleled online experience when they visit the site. Prior to joining Playboy, Saltzman was Senior Director of Digital Product Management at GOAT, and held similar roles at Who What Wear, Ticketmaster and NASA.

“It isn’t enough just to have a website where users can browse a catalog of products, enter their shipping address, and pay,” said Saltzman. “Playboy’s rich history and iconic status as a brand gives us an incredible opportunity to create an innovative, personalized, immersive digital experience where users can not only shop but also explore the world of Playboy – past, present and future. And as a consumer at heart with a deep respect for the Playboy brand, I’m personally very excited for what we can do.”

Tittu Nellimoottil, SVP Data

Nellimoottil brings a modern growth hacking mentality to Playboy and will be working with his team to digitize, consolidate and leverage the nearly seven decades of data that Playboy and its subsidiary Yandy owns, ushering it into the new age of AI-driven, personalized e-commerce. Nellimoottil and his team will build data tools to enable teams across Playboy to make efficient, data-driven decisions at all areas and levels of the business. Prior to Playboy, Nellimoottil served as the Director of Data Science at FabFitFun, was the Technical Lead for Marketplace Data Science at Bird and worked on business credit scores at PayPal. He also holds a PhD in computational biology from the University of Southern California.

“We are a company that is sitting on nearly 70 years of data in many formats, and that is creating millions of connections with consumers every day,” said Nellimoottil. “It’s a goldmine for a data leader like myself, and it poses an immense opportunity and an exciting challenge with a huge reward – utilizing all of that raw data to inform our product innovation, distribution and marketing to better serve consumers today.”

About Playboy

Playboy is one of the largest and most recognizable global lifestyle platforms in the world, with a strong consumer business focused on four categories comprising The Pleasure Lifestyle: Sexual Wellness, Style & Apparel, Gaming & Lifestyle and Beauty & Grooming. Under its mission of Pleasure for All, the 67-year-old Playboy brand drives more than $3 billion in global consumer spend and sells products across 180 countries. Playboy is one of the most iconic brands in history.

About Mountain Crest Acquisition Corp

Mountain Crest Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Mountain Crest Acquisition Corp’s efforts to identify a prospective target business was not limited to a particular industry or geographic region, although the Company focused on operating businesses in North America. Visit https://www.mcacquisition.com/.

Important Information About the Proposed Business Combination and Where to Find It

In connection with the proposed business combination, Mountain Crest intends to file relevant materials with the Securities and Exchange Commission (the “SEC”), which includes the preliminary proxy statement filed on November 10, 2020 with the SEC, and a definitive proxy statement on Schedule 14A, when available. Mountain Crest’s stockholders and other interested persons are advised to read the preliminary proxy statement and the amendments thereto and, when available, the definitive proxy statement and documents incorporated by reference therein filed in connection with the proposed business combination, as these materials will contain important information about Playboy, Mountain Crest, and the proposed business combination. Promptly after filing its definitive proxy statement relating to the proposed business combination with the SEC, Mountain Crest will mail the definitive proxy statement and a proxy card to each stockholder entitled to vote at the special meeting on the business combination and the other proposals. STOCKHOLDERS OF MOUNTAIN CREST ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE BUSINESS COMBINATION THAT MOUNTAIN CREST FILES WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT MOUNTAIN CREST, PLAYBOY, AND THE BUSINESS COMBINATION. Stockholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement, and other relevant materials filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s website at www.sec.gov, or by visiting the investor relations section of https://www.mcacquisition.com/.

Participants in the Solicitation

Mountain Crest and its directors and executive officers may be deemed participants in the solicitation of proxies from Mountain Crest’s stockholders with respect to the business combination. A list of the names of those directors and executive officers and a description of their interests in Mountain Crest , and additional information regarding the interests of such participants are included in the preliminary proxy statement for the proposed business combination available at www.sec.gov. Information about Mountain Crest’s directors and executive officers and their ownership of Mountain Crest common stock is set forth in Mountain Crest’s prospectus, dated June 4, 2020 and in the preliminary proxy statement, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filings. Other information regarding the interests of the participants in the proxy solicitation is included in the preliminary proxy statement pertaining to the proposed business combination. These documents can be obtained free of charge from the sources indicated above.

Playboy and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Mountain Crest in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination is included in the preliminary proxy statement for the proposed business combination.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Mountain Crest’s and Playboy’s actual results may differ from their expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Mountain Crest’s and Playboy’s expectations with respect to future performance and anticipated financial impacts of the proposed business combination, the satisfaction of the closing conditions to the proposed business combination, and the timing of the Mountain Crest shareholders meeting and completion of the proposed business combination.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Mountain Crest’s and Playboy’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change, or other circumstances that could give rise to the termination of the definitive merger agreement (the “Agreement”); (2) the outcome of any legal proceedings that may be instituted against Mountain Crest and Playboy following the announcement of the Agreement and the transactions contemplated therein; (3) the inability to complete the proposed business combination, including due to failure to obtain approval of the stockholders of Mountain Crest, certain regulatory approvals, or satisfy other conditions to closing in the Agreement; (4) the occurrence of any event, change, or other circumstance that could give rise to the termination of the Agreement or could otherwise cause the transaction to fail to close; (5) the impact of COVID-19 pandemic on Playboy’s business and/or the ability of the parties to complete the proposed business combination; (6) the inability to obtain or maintain the listing of Mountain Crest’s shares of common stock on Nasdaq following the proposed business combination; (7) the risk that the proposed business combination disrupts current plans and operations as a result of the announcement and consummation of the proposed business combination; (8) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of Playboy to grow and manage growth profitably, and retain its key employees; (9) costs related to the proposed business combination; (10) changes in applicable laws or regulations; (11) the possibility that Mountain Crest or Playboy may be adversely affected by other economic, business, and/or competitive factors; (12) risks relating to the uncertainty of the projected financial information with respect to Playboy; (13) risks related to the organic and inorganic growth of Playboy’s business and the timing of expected business milestones; (14) the amount of redemption requests made by Mountain Crest’s stockholders; and (15) other risks and uncertainties indicated from time to time in the final prospectus of Mountain Crest for its initial public offering and the proxy statement relating to the proposed business combination, including those under “Risk Factors” therein, and in Mountain Crest’s other filings with the SEC. Mountain Crest cautions that the foregoing list of factors is not exclusive. Mountain Crest and Playboy caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Mountain Crest and Playboy do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Matthew Frappier, ICR for Playboy

203.982.9171

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Publishing Finance Men Communications Professional Services Consumer Books Entertainment

MEDIA:

CORRECTING and REPLACING Medicago and GSK Announce Start of Phase 2/3 Clinical Trials of Adjuvanted COVID-19 Vaccine Candidate

CORRECTING and REPLACING Medicago and GSK Announce Start of Phase 2/3 Clinical Trials of Adjuvanted COVID-19 Vaccine Candidate

The COVID-19 vaccine candidate will contain GSK’s pandemic adjuvant

Phase 3 part of clinical trial to enroll over 30,000 volunteers worldwide

QUEBEC CITY, Quebec & LONDON–(BUSINESS WIRE)–
Please replace the release with the following corrected version due to multiple revisions.

The updated release reads:

MEDICAGO AND GSK ANNOUNCE START OF PHASE 2/3 CLINICAL TRIALS OF ADJUVANTED COVID-19 VACCINE CANDIDATE

The COVID-19 vaccine candidate will contain GSK’s pandemic adjuvant

Phase 3 part of clinical trial to enroll over 30,000 volunteers worldwide

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are pleased to announce the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity. Based on the positive Phase 1 results and the approval of Canadian regulatory authorities, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant.

“Our Phase 1 results of the adjuvanted vaccine candidate were very encouraging and fully support further clinical evaluation,” said Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago.

Thomas Breuer, Chief Medical Officer GSK Vaccines said “This is the first of several GSK COVID-19 vaccine candidate collaborations to start Phase 2/3 clinical testing and an important step forward in our contribution to the global fight against the pandemic. We are delighted with the very promising Phase 1 results of Medicago’s COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant. Proven dose-sparing and a high immune response due to GSK’s adjuvant make us confident of delivering an efficacious vaccine with an acceptable safety profile in collaboration with Medicago.”

The Coronavirus-Like Particle COVID-19 vaccine candidate (CoVLP) is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs).

The study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP (two doses of 3.75 µg CoVLP combined with GSK’s pandemic adjuvant given 21 days apart) has an acceptable immunogenicity and safety profile in healthy adults 18-64 years of age and in elderly subjects aged 65 and over.

The Phase 2 trial part is a randomized, observer-blind, placebo-controlled study to evaluate the safety and immunogenicity of the adjuvanted recombinant COVID-19 plant-derived vaccine candidate in subjects aged 18 and above. It will be conducted in multiple sites in Canada and, upon FDA allowance, in the United States and on a population composed of healthy adults (18-64y) and elderly adults (over 65y). Each age group will have over 300 subjects randomized 5:1 to receive the adjuvanted CoVLP vaccine candidate: placebo and with 2:1 stratification in older adults (65-74 and ≥75). All subjects will be followed for a period of 12 months after the last vaccination for the assessment of safety and durability of the immune responses to the vaccine candidate.

The Phase 3 part of the study should start before the end of 2020 and is an event-driven, randomized, observer-blinded, placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation, compared to placebo, in over 30,000 subjects in North America, Latin America and/or Europe and within the same population, or – alternatively – amongst a broader one pending approval by regulatory authorities.

About Medicago

Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.

Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.

Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.

For more information:www.medicago.com

To learn more about our plant-based technology: Video / Website

About GSK and its commitment to tackling COVID-19

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.

GSK is collaborating with companies and research groups across the world working on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people. GSK does not expect to profit from COVID-19 vaccines during the pandemic phase, and will invest any short-term profit in coronavirus related research and long-term pandemic preparedness, either through GSK internal investments or with external partners.

Medicago Media contact (English):

Alissa Von Bargen

+1-647-234-5975

[email protected]

Medicago Media contact (French):

Marie-Pier Côté

+ 1-418-999-4847

[email protected]

GSK enquiries:

Media enquiries:

Simon Steel, +44 (0) 20 8047 5502 (London)

Simon Moore, +44 (0) 20 8047 5502 (London)

Kathleen Quinn, +1 202 603 5003 (Washington DC)

Analyst/Investor enquiries:

Sarah Elton-Farr, +44 (0) 20 8047 5194 (London)

James Dodwell, +44 (0) 20 8047 2406 (London)

Jeff McLaughlin, +1 215 751 7002 (Philadelphia)

KEYWORDS: Europe United Kingdom North America Canada

INDUSTRY KEYWORDS: Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials

MEDIA:

First Electronic SOFR vs Fed Funds Compression Trade Executed via Bloomberg SEF

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — Today, Bloomberg announced that the first electronic SOFR versus Effective Federal Funds Rate (“EFFR”) basis swap compression trade was executed on the Bloomberg SEF (“BSEF”). The participants successfully executed a 10-year cleared swap unwind (equal and opposite to an original cleared position), using request-for-quote through Bloomberg’s list trading tool, BOLT, to achieve compression of the original position at CME, where the swap was cleared.

Bloomberg supports trading on coupon, basis spread and Net Present Value (NPV), allowing clients to rebalance portfolios from LIBOR to Risk Free Rates. These workflows are complemented by portfolio analytics to calculate margin costs, analyze key rate risk and evaluate what-if scenarios all seamlessly integrated with BOLT.

Clients have had access to trade USD SOFR outright and basis product suite electronically since 2018, alongside offerings in other major currency Risk Free Rate products set to replace LIBOR as market standard.

“The Libor transition requires a synchronized effort, which is essential to a sound and resilient financial system,” said Steven Doherty, director, public investments, Northwestern Mutual. “Executing the first electronic trade using this new enhanced functionality creates efficiencies and supports our goal of maximizing long-term investment returns for our policyowners, while maintaining our unsurpassed financial strength.”

“Libor transition is one of the most important changes in the Rates and FX market today. Wells Fargo’s Macro sales and trading team will remain dedicated to supporting this critical evolution for our clients, including providing technology solutions for efficient execution of SOFR risks,” said James Wang, Global Head of Institutional Interest Rates & Foreign Exchange Sales at Wells Fargo.

“Being the first to market with our SOFR compression trading offering is a clear demonstration of Bloomberg’s commitment to support market participants looking to manage their IBOR exposure,” said Nicholas Bean, Head of Electronic Trading Solutions at Bloomberg. “Clients who trade on Bloomberg continue to have access to deep liquidity alongside the post trade efficiencies that come with electronic execution.”

“Compression is a crucial tool for cleared market participants, and the ability to compress SOFR versus EFFR trades is of particular significance for our clearing members who are looking to boost operational and capital efficiency,” said Sunil Cutinho, President, CME Clearing. “We are pleased to provide this service to clients through services such as Bloomberg SEF and BOLT.”

BSEF provides its participants with electronic trading for CDS, IRS, and FX derivatives built on the core technology behind Bloomberg’s trading platforms, which are used by more than 1,000 global institutions today.

About Bloomberg
Bloomberg, the global business and financial information and news leader, gives influential decision makers a critical edge by connecting them to a dynamic network of information, people and ideas. The company’s strength – delivering data, news and analytics through innovative technology, quickly and accurately – is at the core of the Bloomberg Terminal. Bloomberg’s enterprise solutions build on the company’s core strength: utilizing technology to allow customers to access, integrate, distribute and manage data and information across organizations more efficiently and effectively. For more information, visit Bloomberg.com/company or request a demo.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/first-electronic-sofr-vs-fed-funds-compression-trade-executed-via-bloomberg-sef-301171708.html

SOURCE Bloomberg